Goldman Sachs Group Inc Vbi Vaccines Inc Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	BUY	$0.29 - $0.64 $5,014 - $11,065	17,290 Added 9.64%	196,655 $58,000
Q1 2023 May 11, 2023	BUY	$0.29 - $0.64 $5,014 - $11,065	17,290 Added 9.64%	196,655 $58,000
Q4 2022 May 14, 2024	SELL	$0.38 - $22.5 $46,504 - $2.75 Million	-122,381 Reduced 40.56%	179,365 $69,000
Q4 2022 Feb 13, 2023	SELL	$0.38 - $22.5 $46,504 - $2.75 Million	-122,381 Reduced 40.56%	179,365 $69,000
Q3 2022 May 14, 2024	SELL	$0.73 - $23.4 $662,665 - $21.2 Million	-907,761 Reduced 75.05%	301,746 $213,000
Q3 2022 Nov 10, 2022	SELL	$0.73 - $23.4 $662,665 - $21.2 Million	-907,761 Reduced 75.05%	301,746 $0
Q2 2022 May 14, 2024	BUY	$0.66 - $1.81 $798,274 - $2.19 Million	1,209,507 New	1,209,507 $978,000
Q2 2022 Aug 15, 2022	BUY	$0.66 - $1.81 $135,907 - $372,717	205,921 Added 20.52%	1,209,507 $978,000
Q1 2022 May 16, 2022	SELL	$1.27 - $2.47 $190,475 - $370,453	-149,981 Reduced 13.0%	1,003,586 $1.67 Million
Q4 2021 Feb 14, 2022	BUY	$2.21 - $3.22 $1.81 Million - $2.63 Million	818,173 Added 243.94%	1,153,567 $2.7 Million
Q3 2021 Nov 10, 2021	BUY	$2.8 - $3.72 $939,103 - $1.25 Million	335,394 New	335,394 $1.04 Million

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.